Actively Recruiting
Randomized Study Comparing 26 Cycles of Venetoclax with 6 or 12 Cycles of Epcoritamab for Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2026-10-05
112
Participants Needed
29
Research Sites
195 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of two treatment plans combining the CD3-CD20 T cell engager epcoritamab with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This trial begins with a phase I portion to find the recommended dose of epcoritamab when used with venetoclax, followed by a phase II part to further assess these treatments. Participants receive venetoclax for 26 cycles, starting with a 5-week dose increase phase, combined with either 6 or 12 cycles of epcoritamab. Treatment continues until participants complete their assigned cycles, or until disease progression or severe side effects occur. Two groups are studied in parallel one receiving 6 cycles of epcoritamab plus 26 cycles of venetoclax, and the other receiving 12 cycles of epcoritamab plus 26 cycles of venetoclax. During the study, participants undergo regular assessments including blood and bone marrow tests to measure minimal residual disease and evaluate treatment response. Other evaluations include survival rates, quality of life questionnaires, and monitoring of adverse events. These assessments occur during treatment and continue for up to six years to track long-term outcomes and safety.
CONDITIONS
Brief Title
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Research Team
A
Arnon Kater
M
Mark-David Levin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here